ARTICLE | Financial News
Gene therapy play Orchard raises L21M
May 4, 2016 1:42 AM UTC
Orchard Therapeutics (London, U.K.) raised L21 million ($30.7 million) in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies for primary immune deficiencies, metabolic diseases and hematological disorders. The newco's lead program is a lentiviral gene therapy in the clinic to treat severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).
F-Prime Capital led the round. UCL Business plc also participated, as did the UCL Technology Fund, which University College London launched this year. ...